CHICAGO — The long-acting injectable cabotegravir (ViiV Healthcare), a novel HIV prevention therapy, can persist in the body for more than a year in some people, surprising new data from the phase 2a ...

Both cabotegravir and Truvada were generally safe and well-tolerated. Study participants who received cabotegravir were more likely than those who received placebo shots to report pain and tenderness ...

Two new formulations of the medicine cabotegravir have been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help prevent sexually transmitted HIV-1 infection. A marketing ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study among cisgender ...

(NEW YORK) — Every year almost 38,000 people Americans are diagnosed with HIV. In 2012, the Food and Drug Administration approved groundbreaking medication known as PrEP, or preexposure prophylaxis, ...

Multiple real-world studies show consistent high effectiveness of Vocabria + Rekambys (cabotegravir + rilpivirine LA (CAB+RPV LA)) across a broad range of populations Implementation science data for ...

Please provide your email address to receive an email when new articles are posted on . SEATTLE — Two studies presented at the Conference on Retroviruses and Opportunistic infections demonstrated high ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of key abstracts ...

Initial data from the CLARITY study are first to compare acceptability and tolerability of single-dose cabotegravir (CAB) and lenacapavir (LEN) long-acting injections, in 63 HIV-negative adults ...

DENVER -- Long-acting cabotegravir/rilpivirine (Cabenuva) injectable therapy resulted in similarly high levels of viral suppression to oral antiretroviral therapy ...

Long-acting injections of cabotegravir administered every two months were more effective at preventing HIV than daily Truvada for gay and bisexual men and transgender women, researchers reported last ...